menu

Short Bowel Syndrome Market

Schedule Call

Short Bowel Syndrome Market

Short Bowel Syndrome Market by Drug Class (Glucagon-like Peptide-2, Growth Hormone, Glutamine), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2022-2030

GR - 770856 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: February 21, 2023

Historical Years – 2020  |  Base Year – 2021  |  Forecasted Years – 2022-2030


Short Bowel Syndrome Market Scope

Report Attribute

Details

Market Size Value in 2021

US$ 730.34 million

Revenue Forecast in 2030

US$ 2,366.34 million

CAGR

13.9%

Base year for estimation

2021

Forecast Period

2022-2030

Historical Year

2020

Segments Covered

Drug Class, Distribution Channel, and Region

Regional Scope

North America, Europe, Asia Pacific, and the Rest of the World (RoW)

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global short bowel syndrome market was valued at US$ 730.34 million in 2021 and is expected to register a revenue CAGR of 13.9% to reach US$ 2,366.34 million by 2030.

Short Bowel Syndrome Market Fundamentals

Short bowel syndrome (SBS) is a rare intestinal condition affecting the small intestine and is characterized by malabsorption of nutrients and chronic diarrhea. SBS is a congenital or acquired disorder that can be seen in patients who have had nearly half of their small intestine removed owing to an underlying medical condition. Damaged intestinal tissue, blockage or obstruction in the intestine, gastroschisis, and rotation of the midgut, commonly known as malrotation, are the main causes of small bowel syndrome in children and adults. Crohn’s disease, radiation enteritis, and mesenteric ischemia may result in SBS. This syndrome is most commonly seen following the surgical removal of a large part of the small intestine.

Advancements in diagnostic techniques and medical imaging have led to improvements in the diagnosis rates in SBS patients. Regimen such as intestinal rehabilitation, which aims at maximizing the function of the remaining intestine after surgery, is gaining huge popularity among patients and caregivers alike. Another key trend observed in this market is the advent of stem cell therapy and tissue engineering, along with growth factors, offering new treatment avenues to SBS patients. There is also a growing focus of patients and caregivers on optimum nutrition management. Nutritional management is a crucial aspect of SBS treatment, and there is a growing focus on personalized nutrition plans to meet individual patient needs. The growing number of patient advocacy and support groups is resulting in initiatives to improve patients’ quality of life and education. Furthermore, government bodies in several countries are also offering lucrative incentives for the development of novel treatments for SBS, thus augmenting the market revenue growth. To sum up, the overall trends in the global short bowel syndrome market aim to improve patient treatment outcomes, reduce the need for surgical interventions, and optimize nutrition management and nutrient absorption in patients.

[5675675]

Short Bowel Syndrome Market Dynamics 

Short bowel disease management is improving as knowledge and epidemiological data become more widely available. Furthermore, tremendous advancements in the realm of healthcare have raised awareness of small bowel syndrome, creating opportunities. Along with this, non-profit organizations are fostering research and development in the field of SBS through collaborative scientific study between the public and private sectors. Additionally, State governments, in collaboration with non-profit organizations, offer unique incentives to manufacturers to develop SBS medications. Partnerships between the public and commercial sectors are driving pharmaceutical companies to explore new medications for SBS.

Short Bowel Syndrome Market Ecosystem 

The global short bowel syndrome market has been analyzed from three perspectives: drug class, distribution channel, and region.

Short Bowel Syndrome Market by Drug Class

[8567657]

Based on drug class, the global short bowel syndrome market has been segmented into glucagon-like peptide-2 [GLP2], growth hormone, glutamine, and others.

During the forecast period, the glucagon-like peptide-2 [GLP-2] segment is predicted to dominate the short bowel syndrome market. Gattex/revestive is the only GLP-2 analog in the market for the treatment of SBS. The substantial expansion of this segment can be linked to an increase in Gattex therapy prescriptions, a rise in the number of patients on Gattex therapy, and the high cost of the drug. This medication is commercially available in North America and a few European nations, including the United Kingdom, Germany, France, Italy, Spain, and the Nordics.

Short Bowel Syndrome Market by Distribution Channel 

Based on distribution channel, the global short bowel syndrome market has been segmented into hospital pharmacies, retail pharmacies, and others. 

The hospital pharmacies segment accounts for the largest market revenue share due to the rapid deployment of therapy and a large patient footfall. Furthermore, greater patient preference towards hospitals and the availability of better reimbursement policies facilitate the dominant position of the segment in the global short bowel syndrome market.

Short Bowel Syndrome Market by Region

Based on region, the global short bowel syndrome market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America dominates the short bowel syndrome market and is projected to continue to do so during the forecast period. The rapid expansion of the short bowel syndrome market in North America can be attributable mainly to a rise in Gattex treatment prescriptions in the United States. Furthermore, growth hormones and glutamine have been licensed for the treatment of SBS only in the United States.

Short Bowel Syndrome Market Competitive Landscape 

The prominent players in the global short bowel syndrome market include:

Short Bowel Syndrome Market Strategic Developments 

  • In April 2021, Hanmi Pharmaceutical Company Limited reported that the U.S. FDA had provided fast-track designation to their LAPS GLP-2 Analog treatment for short-bowel syndrome (HM15912). LAPS GLP-2 Analog is a novel biopharmaceutical created for short-bowel syndrome using Labscovery, the company’s platform technology. The condition affects around 24.5 out of every 100,000 babies. It has a significant impact on the growth of children and adolescents, with a survival probability of less than 50%.
  • In December 2020, 9 Meters Biopharma, Inc. reported promising topline results of an open-label phase 1b/2a clinical trial of NM-002, its unique long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, in people with SBS. NM-002 is a long-acting injectable GLP-1 receptor agonist with unique XTEN technology that extends the circulation half-life. This is specifically designed to reduce upper GI motility and improve chronic diarrhea associated with a shorter gut in SBS patients.

Frequently Asked Questions About This Report

Asia Pacific is the key revenue growth region in the global short bowel syndrome market.

The rise in the prevalence of SBS, awareness programs by non-profit organizations, and increasing efforts in the launch of effective treatments and awareness programs by non-profit organizations are propelling revenue growth in the global market.

Takeda Pharmaceuticals U.S.A., EMD Serono, Inc., Emmaus Medical, Inc, Sun Pharmaceuticals Industries Ltd., and Merck KGaA are among the top market players.

The global short bowel syndrome market is expected to be valued at US$ 2.36 billion by 2030.

The global short bowel syndrome market is expected to register growth at a revenue CAGR of 13.9% during the forecast period from 2022 to 2030.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem 
    2. Timeline Under Consideration
      1. Historical Years - 2020
      2. Base Years - 2021
      3. Forecast Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions       
  3. PREMIUM INSIGHTS
    1. Current Market Trend (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL SHORT BOWEL SYNDROME MARKET - ANALYSIS & FORECAST, BY DRUG CLASS 
    1. Glucagon-like Peptide-2 [GLP2]
    2. Growth Hormones
    3. Glutamine
    4. Others (Anti-Diarrheal, Histamine Blocker, Proton Pump Inhibitor, etc.)
  6. GLOBAL SHORT BOWEL SYNDROME MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL 
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Others
  7. GLOBAL SHORT BOWEL SYNDROME MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Short Bowel Syndrome Market
      1. North America Short Bowel Syndrome Market, by Drug Class 
      2. North America Short Bowel Syndrome Market, by Distribution Channel 
      3. North America Short Bowel Syndrome Market, by Country
        1. U.S.
          1. U.S. Short Bowel Syndrome Market, by Drug Class 
          2. U.S. Short Bowel Syndrome Market, by Distribution Channel 
        2. Canada
          1. Canada Short Bowel Syndrome Market, by Drug Class 
          2. Canada Short Bowel Syndrome Market, by Distribution Channel 
    2. Europe Short Bowel Syndrome Market
      1. Europe Short Bowel Syndrome Market, by Drug Class 
      2. Europe Short Bowel Syndrome Market, by Distribution Channel 
      3. Europe Short Bowel Syndrome Market, by Country/Region
        1. Germany
          1. Germany Short Bowel Syndrome Market, by Drug Class 
          2. Germany Short Bowel Syndrome Market, by Distribution Channel 
        2. U.K.
          1. U.K. Short Bowel Syndrome Market, by Drug Class 
          2. U.K. Short Bowel Syndrome Market, by Distribution Channel 
        3. Spain
          1. Spain Short Bowel Syndrome Market, by Drug Class 
          2. Spain Short Bowel Syndrome Market, by Distribution Channel 
        4. Italy 
          1. Italy Short Bowel Syndrome Market, by Drug Class 
          2. Italy Short Bowel Syndrome Market, by Distribution Channel 
        5. France
          1. France Short Bowel Syndrome Market, by Drug Class 
          2. France Short Bowel Syndrome Market, by Distribution Channel 
        6. Rest of Europe 
          1. Rest of Europe Short Bowel Syndrome Market, by Drug Class 
          2. Rest of Europe Short Bowel Syndrome Market, by Distribution Channel 
    3. Asia Pacific Short Bowel Syndrome Market
      1. Asia Pacific Short Bowel Syndrome Market, by Drug Class 
      2. Asia Pacific Short Bowel Syndrome Market, by Distribution Channel 
      3. Asia Pacific Short Bowel Syndrome Market, by Country/Region
        1. China
          1. China Short Bowel Syndrome Market, by Drug Class 
          2. China Short Bowel Syndrome Market, by Distribution Channel 
        2. Japan
          1. Japan Short Bowel Syndrome Market, by Drug Class 
          2. Japan Short Bowel Syndrome Market, by Distribution Channel 
        3. India
          1. India Short Bowel Syndrome Market, by Drug Class 
          2. India Short Bowel Syndrome Market, by Distribution Channel 
        4. South Korea
          1. South Korea Short Bowel Syndrome Market, by Drug Class 
          2. South Korea Short Bowel Syndrome Market, by Distribution Channel 
        5. Australia
          1. Australia Short Bowel Syndrome Market, by Drug Class 
          2. Australia Short Bowel Syndrome Market, by Distribution Channel 
        6. Rest of Asia Pacific 
          1. Rest of Asia Pacific Short Bowel Syndrome Market, by Drug Class 
          2. Rest of Asia Pacific Short Bowel Syndrome Market, by Distribution Channel 
    4. Rest of the World Short Bowel Syndrome Market
      1. Rest of the World Short Bowel Syndrome Market, by Drug Class 
      2. Rest of the World Short Bowel Syndrome Market, by Distribution Channel 
      3. Rest of the World Short Bowel Syndrome Market, By Region
        1. Latin America
          1. Latin America Short Bowel Syndrome Market, by Drug Class 
          2. Latin America Short Bowel Syndrome Market, by Distribution Channel 
        2. Middle East & Africa
          1. Middle East & Africa Short Bowel Syndrome Market, by Drug Class 
          2. Middle East & Africa Short Bowel Syndrome Market, by Distribution Channel 
  8. Pipeline Landscape 
    1. Apraglutide
    2. Glepaglutide
    3. Vurolenatide
    4. HM15912
    5. NM-002
    6. FE203799 GLP-2 analogue
    7. NTRA-9620
    8. Others
  9. COMPANY PROFILES        
    1. Takeda Pharmaceuticals U.S.A.
      1. Business Snapshot 
      2. Products Offered 
      3. Financial Details*
      4. Strategic Developments
    2. EMD Serono, Inc.
    3. Emmaus Medical, Inc
    4. Johnson & Johnson Services, Inc.
    5. Pfizer Inc
    6. Sun Pharmaceuticals Industries Ltd.
    7. Merck KGaA
    8. Zealand Pharma A/S
    9. OxThera
    10. VectivBio AG
    11. 9 Meters Biopharma, Inc
    12. GlyPharma Therapeutics
    13. Hanmi Pharmaceutical Company Limited

*Insights on financial performance is subject to availability of information in public domain

List of Tables

 

  1. Global Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million)
  2. Global Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  3. Global Short Bowel Syndrome Market, By Region, 2020-2030 (US$ Million) 
  4. North America Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  5. North America Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million)
  6. North America Short Bowel Syndrome Market, By Country, 2020-2030 (US$ Million) 
  7. U.S. Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  8. U.S. Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  9. Canada Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  10. Canada Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  11. Europe Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  12. Europe Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  13. Europe Short Bowel Syndrome Market, By Country/ Region, 2020-2030 (US$ Million) 
  14. Germany Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  15. Germany Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  16. U.K. Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  17. U.K. Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  18. France Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  19. France Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  20. Italy Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  21. Italy Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  22. Spain Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  23. Spain Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  24. Rest of Europe Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  25. Rest of Europe Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  26. Asia Pacific Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  27. Asia Pacific Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  28. Asia Pacific Short Bowel Syndrome Market, By Country/ Region, 2020-2030 (US$ Million) 
  29. China Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  30. China Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  31. Japan Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  32. Japan Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  33. India Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  34. India Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  35. South Korea Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  36. South Korea Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  37. Australia Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  38. Australia Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  39. Rest of Asia Pacific Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  40. Rest of Asia Pacific Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  41. Rest of the World Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  42. Rest of the World Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  43. Rest of the World Short Bowel Syndrome Market, By Region, 2020-2030 (US$ Million) 
  44. Latin America Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  45. Latin America Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 
  46. Middle East and Africa Short Bowel Syndrome Market, By Drug Class, 2020-2030 (US$ Million) 
  47. Middle East and Africa Short Bowel Syndrome Market, By Distribution Channel, 2020–2030 (US$ Million) 

List of Figures

 

  1. Short Bowel Syndrome Market Ecosystem  
  2. Snapshot of Global Short Bowel Syndrome Market, 2020-2030 
  3. Snapshot of Global Short Bowel Syndrome Market, By Region, 2020-2030 
  4. Global Short Bowel Syndrome Market: COVID-19 Pandemic Impact Assessment 
  5. Global Short Bowel Syndrome Market: Key Players & Competitive Positioning (2021) 
  6. Short Bowel Syndrome: Market Dynamics
  7. Global Short Bowel Syndrome Market for Glucagon-like Peptide-2 [GLP2], 2020-2030 (US$ Million) 
  8. Global Short Bowel Syndrome Market for Growth Hormones, 2020-2030 (US$ Million) 
  9. Global Short Bowel Syndrome Market for Glutamine, 2020-2030 (US$ Million) 
  10. Global Short Bowel Syndrome Market for Drug Classes, 2020-2030 (US$ Million) 
  11. Global Short Bowel Syndrome Market for Hospital Pharmacies, 2020-2030 (US$ Million) 
  12. Global Short Bowel Syndrome Market for Retail Pharmacies, 2020-2030 (US$ Million) 
  13. Global Short Bowel Syndrome Market for Distribution Channels, 2020-2030 (US$ Million)
  14. North America Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  15. U.S. Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  16. Canada Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  17. Europe Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  18. Germany Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  19. U.K. Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  20. France Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  21. Italy Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  22. Spain Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  23. Rest of Europe Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  24. Asia Pacific Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  25. China Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  26. Japan Short Bowel Syndrome Market, 2020-2030 (US$ Million)
  27. India Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  28. South Korea Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  29. Australia Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  30. Rest of Asia Pacific Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  31. Rest of the World Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  32. Latin America Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  33. Middle East & Africa Short Bowel Syndrome Market, 2020-2030 (US$ Million) 
  34. Takeda Pharmaceuticals U.S.A. Revenue from 2018-2021 (US$ Billion)
  35. EMD Serono, Inc. Revenue from 2018-2021 (US$ Billion)
  36. Emmaus Medical, Inc. Revenue from 2018-2021 (US$ Billion)
  37. Johnson & Johnson Services, Inc. Revenue from 2018-2021 (US$ Billion)
  38. Pfizer Inc. Revenue from 2018-2021 (US$ Billion)
  39. Sun Pharmaceuticals Industries Ltd. Revenue from 2018-2021 (US$ Billion)
  40. Merck KGaA Revenue from 2018-2021 (US$ Billion)
  41. Zealand Pharma A/S Revenue from 2018-2021 (US$ Billion)
  42. OxThera Revenue from 2018-2021 (US$ Billion)
  43. VectivBio AG Revenue from 2018-2021 (US$ Billion)
  44. 9 Meters Biopharma, Inc Revenue from 2018-2021 (US$ Billion)
  45. GlyPharma Therapeutics Revenue from 2018-2021 (US$ Billion)
  46. Hanmi Pharmaceutical Company Limited Revenue from 2018-2021 (US$ Billion)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Short Bowel Syndrome Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Short Bowel Syndrome Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports